Publication date: Jul 04, 2025
As you can imagine, and as you probably know, the majority of the patients that are diagnosed with melanoma are actually diagnosed at an early stage. We have data from the DREAMseq trial saying that patients will probably benefit more from immunotherapy upfront, even when they have a BRAF mutation. Actually, these have been pretty promising for predicting the risk for recurrence of these early-stage patients. Its very interesting to see that this has been selected to be discussed here. Well, that was part of the prevention, and now we go to early-stage melanoma. For stage II, we have immunotherapy. First, for early-stage trials, and again, looking into trials that are biomarker-selected. Why is this poster interesting?
| Concepts | Keywords |
|---|---|
| Cancers | Adjuvant |
| June | Benefit |
| Meeting | Early |
| Ultrasounds | Immunotherapy |
| Viral | Interesting |
| Majority | |
| Melanoma | |
| Pd | |
| Population | |
| Presented | |
| Stage | |
| Targeted | |
| Therapy | |
| Trial | |
| Trials |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | metastasis |
| disease | MESH | brain metastases |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | recurrence |
| disease | MESH | tumors |
| pathway | KEGG | Melanoma |
| disease | MESH | Skin Cancer |
| disease | MESH | Melanoma |